Phase 3 N=705 A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
Migraine Disorders
Primary: Change in Frequency of Headache Days — 19.9; 19.7; -9.0; -6.7 Headache Days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=364 Treatment of Latent TB Infection for Jailed Persons
Tuberculosis
Primary: Number of Participants With Laboratory Test or Clinical Judgment Resulting in the Need to Stop Study Medication — 6; 3 participants — p=>.05
Phase 3 N=192 IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity
Upper Limb Spasticity
Primary: Responder in Disability Assessment Scale (DAS) at Week 4 - Per Protocol Set — 51; 44 participants
Phase 3 N=639 Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials
Rheumatoid Arthritis
Primary: Total Exposure to Etanercept With Gaps — 4033.07; 341.98 Participant-years
Phase 3 N=1,703 Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)
Migraine
Primary: Number of Patients Reporting Pain Freedom at 2 Hours Postdose — 29; 88; 88; 39 Participants — p=<0.001
Phase 3 N=121 Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face
Skin Aging
Primary: Treatment Success — 89.08 % of participants
Phase 3 N=278 Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight — 5; 6; 4; 7 participants
Phase 3 N=108 ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults
Alcoholism
Primary: Number of Participants Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) — 49; 51 Participants
Phase 3 N=1,042 Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age
Tetanus · Diphtheria · Pertussis
Primary: Percentage of Participants Who Achieved Seroprotection at Baseline and 30 Days Post-vaccination for Diphtheria and Tetanus at ≥ 0.1 IU/mL Level — 65; 69; 100; 100…
Phase 3 N=139 A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
Glaucoma
Primary: Reduction From Baseline in Mean IOP at Week 12, Last Observation Carried Forward (LOCF) — 5.72; 7.18 mmHg
Phase 3 N=110 Antioxidant Supplementation in Pregnant Women
Pregnant Women · Preeclampsia
Primary: Preeclampsia
Phase 3 N=591 A Study of Abatacept in Patients With Active Ulcerative Colitis
Ulcerative Colitis
Primary: Induction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C) — 30; 26; 14; 41 participants — p=0.124
Phase 3 N=1,649 A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel
Acne Vulgaris · Acne
Primary: Absolute Change From Baseline in Lesion Counts (Total, Inflammatory, and Non-inflammatory) at Week 12 (End of Study) — -15.5; -14.5; -13.9; -11.1 lesions — p=0.063
Phase 3 N=244 Analgesic Efficacy & Safety of Intravenous (IV) Acetaminophen Versus Placebo for the Treatment of Postop Pain
Pain
Primary: Sum Pain Intensity Difference - Baseline to 24 Hours (SPID24), 1 g IV Acetaminophen vs. Placebo (PI Was Measured at the Timepoints of T0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10…
Phase 3 N=32 Varenicline For Smokers In Recovery From Alcohol Dependence
Tobacco Abstinence
Primary: Biochemically Confirmed Abstinence From Smoking — 10 participants